Chuck Schumer hospitalized for dehydration as record heatwave grips Washington
Senate Majority Leader Chuck Schumer (D-NY) answers reporters questions during a press conference following the weekly Senate caucus luncheons on Capitol Hill in Washington,US.PHOTO: REUTER
Senate Minority Leader Chuck Schumer, D-N.Y., was briefly hospitalized Wednesday morning after experiencing lightheadedness during an intense heatwave sweeping across Washington, D.C.
According to a statement from his office, Schumer felt unwell while at the Senate gym and was taken to the hospital as a precaution.
'Leader Schumer was at the Senate gym this morning and got lightheaded,' his office told Fox News. 'Out of an abundance of caution, he went to the hospital to be treated for dehydration and is now back at work in the Capitol.'
The incident occurred as the U.S. capital experienced dangerously high temperatures, with heat indexes climbing above 105°F. The Washington D.C. Homeland Security & Emergency Management Agency issued an Extreme Heat Alert warning residents to stay indoors, remain hydrated, and avoid prolonged sun exposure.
Chuck Schumer was hospitalized this morning for what his office claims was dehydration pic.twitter.com/1pp6ja0BZK — Ken Klippenstein (@kenklippenstein) June 25, 2025
Schumer, 73, was evaluated, treated, and released in time to resume his duties on Capitol Hill by lunchtime. He used the opportunity to remind the public to take heat warnings seriously. 'Drink some water and stay out of the heat,' he said, according to his office.
This comes as nearly 150 million Americans across the East Coast and Midwest remain under heat advisories. The National Weather Service continues to issue alerts as the record-breaking heatwave is expected to last through Friday.
Health officials urge the public to monitor for signs of heat exhaustion, especially among the elderly and those with pre-existing health conditions.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Express Tribune
11 hours ago
- Express Tribune
Chuck Schumer hospitalized for dehydration as record heatwave grips Washington
Senate Majority Leader Chuck Schumer (D-NY) answers reporters questions during a press conference following the weekly Senate caucus luncheons on Capitol Hill in Washington, REUTER Senate Minority Leader Chuck Schumer, D-N.Y., was briefly hospitalized Wednesday morning after experiencing lightheadedness during an intense heatwave sweeping across Washington, D.C. According to a statement from his office, Schumer felt unwell while at the Senate gym and was taken to the hospital as a precaution. 'Leader Schumer was at the Senate gym this morning and got lightheaded,' his office told Fox News. 'Out of an abundance of caution, he went to the hospital to be treated for dehydration and is now back at work in the Capitol.' The incident occurred as the U.S. capital experienced dangerously high temperatures, with heat indexes climbing above 105°F. The Washington D.C. Homeland Security & Emergency Management Agency issued an Extreme Heat Alert warning residents to stay indoors, remain hydrated, and avoid prolonged sun exposure. Chuck Schumer was hospitalized this morning for what his office claims was dehydration — Ken Klippenstein (@kenklippenstein) June 25, 2025 Schumer, 73, was evaluated, treated, and released in time to resume his duties on Capitol Hill by lunchtime. He used the opportunity to remind the public to take heat warnings seriously. 'Drink some water and stay out of the heat,' he said, according to his office. This comes as nearly 150 million Americans across the East Coast and Midwest remain under heat advisories. The National Weather Service continues to issue alerts as the record-breaking heatwave is expected to last through Friday. Health officials urge the public to monitor for signs of heat exhaustion, especially among the elderly and those with pre-existing health conditions.
Express Tribune
a day ago
- Express Tribune
Nearly half the US population face scorching heat wave
Tens of millions of Americans sweltered outside or sought air-conditioned refuge as an "extremely dangerous" heat wave blanketed the eastern United States on Tuesday with record high temperatures. As a fierce sun reflected off the skyscrapers of New York, the normally frenetic Times Square was virtually deserted by mid-day as the mercury reached 99 degrees Fahrenheit (37 Celsius), the hottest since 2012 in the Big Apple. By mid-afternoon Newark, New Jersey hit 103F (39.4C), according to the National Weather Service, and Philadelphia also reached 100F (38C). New Yorkers walked under umbrellas as they navigated the streets of Manhattan, while others sunbathed in swimsuits in parks. "It's been kind of a cold spring. Then all of a sudden, boom, here it is," Eleanor Burke, 82, told AFP of the heat, recalling how she took a dog for a walk the night before and "he almost looked like he was dead." Soaring temperatures are straining the city's power grid as people crank up their air conditioning. In the Bronx, a New York borough, a blackout left more than 34,000 homes without power, prompting energy supplier Con Edison to urge residents to moderate their electricity consumption. The NWS warned of East Coast temperatures of 97F-103F (36C-39.4C) on Tuesday, and a heat index — what the temperature feels like with humidity factored in -— spiking as high as 110F (43.3C) for the New York metropolitan area. AFP
Business Recorder
31-05-2025
- Business Recorder
US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older
The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements. The vaccine has also been approved for people aged 12 to 64 with at least one or more underlying risk factors defined by the Centers for Disease Control and Prevention, Moderna said in a statement. The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' CEO Stephane Bancel said in the statement. The Department of Health and Human Services, under the leadership of long-time vaccine skeptic Robert F. Kennedy Jr., is tightening regulatory scrutiny on vaccines. The FDA said on May 20 it planned to require drugmakers to test their COVID booster shots against an inert placebo in healthy adults under 65 for approval, effectively limiting them to older adults and those at risk of developing severe illness. The Moderna vaccine can be stored in refrigerators rather than freezers, to offer longer shelf life and make distribution easier, especially in developing countries where supply-chain issues could hamper vaccination drives. The Centers for Disease Control and Prevention, which Kennedy also oversees, said on Thursday that COVID vaccines remain an option for healthy children when parents and doctors agree that it is needed, stopping short of Kennedy's announcement days earlier that the agency would remove the shots from its immunization schedule. The CDC announcement eases investor concern to some extent, analysts say, as it keeps the existing framework for older adults and at-risk people who generally seek out the shots. FDA leaders have said 100 million to 200 million Americans would still be eligible for annual shots. Moderna is betting on its newer messenger RNA vaccines as it grapples with waning demand for its original COVID vaccine Spikevax and lower-than-expected uptake of its respiratory syncytial virus vaccine. The approval for mNEXSPIKE was based on late-stage trial data, which showed the shot was not inferior in efficacy compared to Spikevax in individuals aged 12 years and older. The shot also showed superior efficacy compared to Spikevax in adults 18 years of age and older in the study. Kennedy has kickstarted a major overhaul of health departments, laying off thousands of employees to align with President Donald Trump's goal of dramatically shrinking the federal government. This has further ignited worries about potential disruptions to the regulatory review of treatments and vaccines. The CDC's outside panel of vaccine experts in April discussed recommending the booster shots only for populations at risk of severe COVID-19 for the upcoming immunization campaign. The FDA approved Novavax's COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness. Conditions that constitute additional risk range from illnesses such as diabetes and heart disease to behaviors like physical inactivity and substance abuse, according to the CDC. While Moderna's shots, as well as Pfizer-BioNTech's Comirnaty, are mRNA-based, Novavax's vaccine is protein-based and takes longer to manufacture. Moderna this month withdrew an application seeking approval for its flu-and-COVID combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot.
